Ocugen reports Q4 EPS (5c), consensus (5c)

Reports Q4 revenue $764k, consensus $300k. “I am extremely proud of our team at Ocugen (OCGN), who are working tirelessly to enroll patients across all four clinical programs in close collaboration with the study centers and investigators,” said Dr. Huma Qamar, Chief Medical Officer at Ocugen. “It is very gratifying to think about the potential unmet medical need that can be addressed through modifier therapy for patients who currently have no options and are facing the prospect of losing their vision altogether.”